C07K 14/70528
Cd58
Official title: {cd58}
C07K14/70528 (Cd58) appears on 35 US grants and 41 published applications in this corpus.
Search patents in C07K- Granted patents
- 35
- Published applications
- 41
- Assignees
- 33
- Inventors
- 128
- Latest grant
- 11 Feb 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 3 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 2 | 0 |
| 1997 | 1 | 0 |
| 1998 | 2 | 0 |
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 2 |
| 2003 | 1 | 0 |
| 2004 | 3 | 4 |
| 2005 | 1 | 1 |
| 2006 | 0 | 1 |
| 2007 | 2 | 1 |
| 2008 | 2 | 4 |
| 2009 | 0 | 2 |
| 2010 | 3 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 2 |
| 2021 | 1 | 4 |
| 2022 | 1 | 1 |
| 2023 | 1 | 5 |
| 2024 | 2 | 3 |
| 2025 | 1 | 7 |
| 2026 | 0 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- CD19 binding molecules and uses thereof11 Feb 2025US 12,221,481 B2Novartis AG
- Lymphocyte function-associated antigen 3 (LFA3) variant polypeptides and methods of use thereof to treat CD2-mediated immune diseases, disorders or conditions1 Oct 2024US 12,103,958 B2Pfizer Inc.
- Variant CD58 domains and uses thereof16 Jul 2024US 12,037,378 B2Novartis AG
- Compositions and methods for enhancing the stability of transgenes in poxviruses23 May 2023US 11,654,189 B2Bavarian Nordic A/S
- Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use6 Sep 2022US 11,434,276 B2Invetx, Inc.
- Lentiviral delivery of anti-cd20 chimeric antigen receptors8 Oct 2026US 2026/0308622 A1
- Particles displaying adhesion-molecule fusions25 Jun 2026US 2026/0176651 A1Umoja Biopharma, Inc.
- Lentiviral particles displaying fusion molecules and uses thereof18 Jun 2026US 2026/0166143 A1Umoja Biopharma, Inc.
- Dosage regimens for anti-cd19 agents and uses thereof6 Nov 2025US 2025/0340634 A1Novartis AG
- Cd19 binding molecules and uses thereof10 Jul 2025US 2025/0223359 A1Novartis AG
Most cited
By later US patents
- Chimeric receptor molecules for delivery of co-stimulatory signals260US 5,686,281 ACell Genesys, Inc. · 1997
- Chimeric receptor molecules for delivery of co-stimulatory signals162US 5,712,149 ACell Genesys, Inc. · 1998
- Alteration of Fc-fusion protein serum half-lives by mutagenesis84US 7,217,798 B2PDL BioPharma, Inc. · 2007
- DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-371US 4,956,281 ABiogen, Inc. · 1990
- Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction67US 6,162,432 ABiogen, Inc. · 2000